Logo 1.png
Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s Disease)
May 17, 2021 08:05 ET | Aeterna Zentaris Inc
- Aeterna Zentaris granted exclusive option to negotiate a license of any resulting intellectual property and know-how developed by the University related to the therapeutic use of macimorelin for the...
Logo 1.png
Aeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism
May 06, 2021 08:05 ET | Aeterna Zentaris Inc
 –In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical...
Logo.jpg
Biofrontera AG: First quarter conference call to be held on May 12, 2021
May 03, 2021 09:40 ET | Biofrontera AG
Leverkusen, Germany, May 03, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its ...
logo.jpg
Vallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation Forum
April 26, 2021 09:05 ET | Vallon Pharmaceuticals Inc.
David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel on April 29th at 10:30 AM ET PHILADELPHIA, PA, April 26, 2021 (GLOBE NEWSWIRE) -- Vallon...
logo.png
Adhera Therapeutics Appoints Trond K. Waerness to Board of Directors
April 23, 2021 09:00 ET | Adhera Therapeutics, Inc.
Baton Rouge, LA, April 23, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera Therapeutics" or the "Company"), a clinical stage biopharmaceutical company engaged in the...
Logo.jpg
Biofrontera announces preliminary revenue for Q1 2021
April 08, 2021 10:30 ET | Biofrontera AG
Leverkusen, Germany, April 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Logo.jpg
Biofrontera announces conference call to be held on April 13, 2021 to discuss fiscal year 2020 financial results
March 31, 2021 10:12 ET | Biofrontera AG
Leverkusen, Germany, March 31, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing...
Logo.jpg
Biofrontera submits application for FDA approval of new BF-RhodoLED® XL lamp
March 31, 2021 03:40 ET | Biofrontera AG
Leverkusen, Germany, March 31, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced the...
Logo 1.png
Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Requirement
March 22, 2021 16:05 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., March 22, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
LOGO.png
The Greater Cannabis Company Announces Relisting to OTCQB
March 09, 2021 08:00 ET | The Greater Cannabis Company, Inc.
BALTIMORE, March 09, 2021 (GLOBE NEWSWIRE) -- The Greater Cannabis Company, Inc. (OTCQB: GCAN) (“the Company”), a biopharmaceutical company focused on development and commercialization of innovative...